GLP-3 (Retatrutide) Research Guide: The Triple-Agonist Pathway

What Is Retatrutide / GLP-3?

Retatrutide (developmental code LY3437943) is a synthetic peptide developed as a novel multi-receptor agonist for metabolic-pathway research. The "GLP-3" nickname has emerged in the peptide-research community to describe its evolutionary position in the GLP-receptor agonist research timeline:

• "GLP-1" — single-pathway agonists (semaglutide, liraglutide)
• "GLP-2" — informal name for dual-receptor agonists like tirzepatide (GIP + GLP-1)
• "GLP-3" — informal name for triple-receptor agonists like retatrutide (GIP + GLP-1 + glucagon)

The "GLP-3" label is informal and not technical — there's no actual GLP-3 receptor. But it has stuck in research forums as shorthand for "third-generation triple-receptor metabolic agonist."

Triple-Receptor Mechanism Explained

What makes retatrutide pharmacologically distinct is that it activates three different incretin / glucoregulatory pathways simultaneously:

1. GLP-1 Receptor (Glucagon-Like Peptide 1)

The same pathway activated by semaglutide and liraglutide. In research models, GLP-1 receptor activation is associated with:

• Glucose-dependent insulin secretion
• Slowed gastric emptying (satiety pathway research)
• Central nervous system signaling related to food-intake regulation

2. GIP Receptor (Glucose-Dependent Insulinotropic Polypeptide)

The second pathway added by tirzepatide. GIP-receptor research has shown effects on:

• Insulin secretion (synergistic with GLP-1)
• Adipose-tissue metabolism in research models
• Energy expenditure pathway interactions

3. Glucagon Receptor

The novel addition in retatrutide. Glucagon-receptor activation in research models is investigated for:

• Hepatic lipid metabolism
• Energy expenditure (a counterintuitive but well-documented effect — glucagon agonism in research is associated with increased energy expenditure)
• Glucose-output regulation

The interesting hypothesis behind triple-agonism research: by activating glucagon-receptor pathways alongside GLP-1 and GIP, researchers can investigate energy-expenditure mechanisms that single- or dual-agonist research cannot reach.

Retatrutide vs Semaglutide vs Tirzepatide

For researchers comparing the GLP-receptor agonist class, the key distinguishing features:

Compound	Receptor Activity	Research Generation
Semaglutide	GLP-1 only	1st generation single-agonist
Tirzepatide	GLP-1 + GIP (dual)	2nd generation dual-agonist
Retatrutide (GLP-3)	GLP-1 + GIP + Glucagon (triple)	3rd generation triple-agonist

The progression isn't strictly "newer = better" — each receptor profile is appropriate for different research questions. Retatrutide's triple-pathway activity makes it a particularly interesting research tool for metabolic-axis studies that want to investigate energy expenditure alongside glucose regulation, which the earlier dual- and single-agonist compounds can't reach as cleanly.

What the Published Research Shows

The published peer-reviewed research on retatrutide is still relatively early but substantial:

Phase 2 Clinical Research (2023, NEJM)

The most-cited published study is the 2023 New England Journal of Medicine phase 2 dose-finding investigation. The study reported dose-dependent effects on weight and metabolic markers across a range of dosing levels, with effects substantially larger than what dual-agonist compounds had shown in comparable dose-ranging studies.

Hepatic Steatosis Research

A separate published investigation examined retatrutide's effects in research participants with hepatic steatosis (fatty liver). Liver-fat-fraction reductions across the study's higher-dose arms were notable in the published results.

Metabolic Markers

Across the published studies, the metabolic-marker changes tracked include HbA1c, fasting glucose, lipid panels, and body-composition measures. The results are dose-dependent and the high-dose arms showed effects considerably stronger than what semaglutide or tirzepatide had shown in comparable research.

Common Research Protocol Designs

Research protocols investigating retatrutide typically follow patterns established by the GLP-1 / dual-agonist research literature:

Dose Escalation

Published studies generally use a dose-escalation approach — starting at low doses (research models) and increasing weekly or biweekly. This is methodologically important because:

• Triple-pathway activation produces stronger pharmacological effects than single- or dual-pathway, requiring careful titration in research designs
• GI-pathway side effects in research models are dose-dependent
• Slow titration produces more interpretable dose-response data

Weekly Dosing

Like other long-acting GLP-receptor agonists, retatrutide's research-protocol dosing is weekly (subcutaneous administration). The half-life supports once-weekly dosing in study designs.

Long Study Durations

Metabolic-pathway research protocols using retatrutide typically run 12–48 weeks because the metabolic adaptations being investigated require extended time courses.

Co-Administration Considerations: Retatrutide + MOTS-C

The most-investigated research pairing involving retatrutide is with MOTS-C — a mitochondrial-derived peptide that activates the AMPK pathway. The mechanistic rationale:

• Retatrutide: Activates incretin and glucagon-receptor pathways at the systemic / endocrine level
• MOTS-C: Activates AMPK at the cellular / mitochondrial level

The two pathways act on metabolic regulation at different biological scales (systemic vs. cellular), making the pairing methodologically interesting for research investigating the energy-coupling axis. See our MOTS-C research guide for the full pairing rationale.

Sourcing Research-Grade Retatrutide

Retatrutide is a complex synthetic peptide and its synthesis is not trivial. For research-grade supply, look for:

• HPLC purity ≥ 99% — retatrutide's research dosing range means even small purity differences produce meaningful effective-dose differences
• Mass-spec confirmation — confirms the correct molecular weight (~4,731 Da) and validates against the LY3437943 reference structure
• Lyophilized form — research-grade retatrutide should ship as lyophilized powder for reconstitution with bacteriostatic water
• Recent COA — synthesis dates within 12 months for confidence in stability

Elytra Labs publishes batch-specific COAs for our retatrutide research supply. Browse our current COA library →